{"id":190846,"date":"2021-02-12T17:14:00","date_gmt":"2021-02-12T17:14:00","guid":{"rendered":"https:\/\/bm.dev.synology.me\/?p=190846"},"modified":"2021-02-12T17:14:00","modified_gmt":"2021-02-12T17:14:00","slug":"incepe-prima-faza-de-testare-pe-oameni-a-unui-nou-vaccin-produs-in-italia","status":"publish","type":"post","link":"https:\/\/bm.dev.synology.me\/?p=190846","title":{"rendered":"\u00cencepe prima faz\u0103 de testare pe oameni a unui nou vaccin produs \u00een Italia"},"content":{"rendered":"<p>\nTestarea \u00eencepe din 1 martie la spitalul San Gerardo din Monza, spitalul Spallanzani din Roma \u015fi la Institutul Pascale din Napoli, scrie La Stampa.<\/p>\n<p>\nMarina Cazzaniga, directorul Centrului din Monza, a declarat c\u0103 str\u00e2ngerea adeziunilor pentru experimentarea vaccinului a \u00eenceput \u00een august, iar acum studiul a primit autoriza\u0163ia AIFA \u015fi a Comitetului de Etic\u0103 al Institutului Spallanzani.<\/p>\n<p>\nPrima faz\u0103 de testare va implica aproximativ 80 de persoane, \u201eto\u0163i voluntari s\u0103n\u0103to\u015fi\u201d de diferite v\u00e2rste, \u00een timp ce \u00een faza a doua se va ajunge la aproximativ 200 de voluntari.<\/p>\n<p>\nPotrivit prof. Paolo Bonfanti, profesor asociat de boli infec\u0163ioase al Universit\u0103\u0163ii Bicocca din Milano, \u201evaccinul este inovator deoarece, spre deosebire de altele testate, nu folose\u015fte un vector viral pentru producerea de anticorpi, cum ar fi un adenovirus inactivat, ci este alc\u0103tuit dintr-un fragment de ADN care, odat\u0103 injectat \u00een mu\u015fchi, stimuleaz\u0103 o reac\u0163ie imun\u0103 care previne infec\u0163ia\u201d.<\/p>\n<p>\nMai mult, vaccinul ar putea deveni important \u00een contextul \u00een care exist\u0103 posibilitatea modific\u0103rii acestuia prin adaptarea la apari\u0163ia variantelor noi de virus.<\/p>\n<p>\nAutorit\u0103\u0163ile italiene spuneau, \u00een ianuarie, despre primul vaccin produs \u00een Italia, de c\u0103tre compania ReiThera, c\u0103 a demonstrat c\u0103 este sigur \u00een faza 1 de testare \u015fi a indus un r\u0103spuns imun pe subiec\u0163i. 92,5 % dintre cei vaccina\u0163i aveau niveluri de anticorpi detectabili.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Testarea pe oameni a vaccinului italian Rottapharm-Takis \u00eencepe din 1 martie. \u00cen prima faz\u0103 vaccinul va fi testat pe 80 de voluntari, iar \u00een cea de-a doua pe 200.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[510],"tags":[7507,14930],"class_list":["post-190846","post","type-post","status-publish","format-standard","hentry","category-actualitate","tag-italia","tag-vaccin"],"_links":{"self":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/190846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=190846"}],"version-history":[{"count":0,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/190846\/revisions"}],"wp:attachment":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=190846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=190846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=190846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}